A Phase 2 trial of MYMD-1 in Autoimmune disorders
Latest Information Update: 30 Jul 2024
At a glance
- Drugs Isomyosamine (Primary)
- Indications Autoimmune disorders
- Focus Therapeutic Use
- 19 Apr 2021 According to a MyMD Pharmaceuticals media release, this study is expected to begin during the near term with results expected by year end 2021.
- 24 Nov 2020 New trial record
- 12 Nov 2020 According to a MyMD Pharmaceuticals media release, this study is expected to begin in Q1 2021.